...Yes. Thank you, Mark. And obviously, it's a pleasure to be here and talk to you about where Sanofi is currently and about any questions that you have, obviously. Really, as a quick introduction, we have laid out our strategy in 2019 at the Capital Markets Day. We have highlighted a few key assets at that point in time. We've highlighted our ambition for Dupixent but also for the broader portfolio. And to me, it's good to see how far we've come over the last 2 years that really the strategy still holds and still stands. And we're doing something that I consider it's not without precedent but it's obviously a challenge which is transforming the company and rebuilding the pipeline at the same time. And personally, I feel we have made really good progress on that over the last 18 months. We've significantly transformed the pipeline at a much stronger focus, have added a much stronger focus on immunology and oncology as well. We've rigorously prioritized our project. We started 10 Phase III...
